Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The 2019 coronavirus disease (Covid-19) is a new disease caused by the SARS-CoV2 virus of which many things are not yet known. Among others, there is a need to define the best therapeutic strategy to treat Covid-19, improving patients survival and reducing complications in its management, for which many different types of treatments are being tested. The drug being tested in this clinical trial is called bemiparin. Bemiparin is a drug authorized as a prevention and as a treatment for deep vein thrombosis (blood clots in one or more veins, generally in the legs) and venous thromboembolism (when the clot can detach and lodge in other organs such as the lungs). Covid-19 patients have been shown to be at increased risk of developing clotting problems such as those described above. In this context, this clinical trial is being carried out to find out if certain doses of bemiparin can contribute to better management of the disease.
Description: Combined worsening variable. Presence of any of the following will be considered worseing: Death. ICU admission. Need for either non-invasive or invasive mechanical ventilation. Progression to moderate / severe respiratory distress syndrome according to objective criteria (Berlin definition). Venous thromboembolism (deep vein thrombosis or pulmonary embolism) or arterial (acute myocardial infarction or stroke).
Measure: Proportion of patients that worsen Time: Day 10 +/- 1Description: Mortality from any cause
Measure: Mortality from any cause at day 28 Time: Day 28Description: Proportion of subjects that requires admission to the ICU
Measure: Proportion of subjects that requires admission to the ICU Time: From study start to day 28Description: Proportion of subjects requiring non-invasive mechanical ventilation
Measure: Proportion of subjects requiring non-invasive mechanical ventilation Time: From study start to day 28Description: Proportion of subjects requiring invasive mechanical ventilation.
Measure: Proportion of subjects requiring invasive mechanical ventilation. Time: From study start to day 28Description: Proportion of subjects with some organ failure
Measure: Proportion of subjects with some organ failure Time: From study start to day 28Description: Proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline
Measure: Proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline Time: From study start to day 28Description: Proportion of subjects with pathological angioTAC at day 10 +/-1
Measure: Proportion of subjects with pathological angioTAC Time: At day 10 +/-1Description: Proportion of subjects with improvement in chest radiography
Measure: Proportion of subjects with improvement in chest radiography Time: At day 10 +/-1Description: Proportion and median hospital discharge between patients in both groups.
Measure: Proportion and median hospital discharge between patients in both groups. Time: From study start to day 28Description: Titration score
Measure: Titration score Time: From study start to day 28Description: Ferritin score
Measure: Ferritin score Time: From study start to day 28Description: D-dimer modification score
Measure: D-dimer modification score Time: From study start to day 28Description: Adverse events (total and serious)
Measure: Adverse events (total and serious). Time: From study start to day 28Description: Related adverse events (total and serious).
Measure: Related adverse events (total and serious). Time: From study start to day 28Description: Clinically relevant major and non major hemorrhages.
Measure: Clinically relevant major and non major hemorrhages. Time: From study start to day 28The 2019 coronavirus disease (Covid-19) is a new disease caused by the SARS-CoV2 virus of which many things are not yet known. Among others, there is a need to define the best therapeutic strategy to treat Covid-19, improving patients survival and reducing complications in its management, for which many different types of treatments are being tested. The drug being tested in this clinical trial is called bemiparin. Bemiparin is a drug authorized as a prevention and as a treatment for deep vein thrombosis (blood clots in one or more veins, generally in the legs) and venous thromboembolism (when the clot can detach and lodge in other organs such as the lungs). Covid-19 patients have been shown to be at increased risk of developing clotting problems such as those described above. In this context, this clinical trial is being carried out to find out if certain doses of bemiparin can contribute to better management of the disease.
Description: Combined worsening variable. Presence of any of the following will be considered worseing: Death. ICU admission. Need for either non-invasive or invasive mechanical ventilation. Progression to moderate / severe respiratory distress syndrome according to objective criteria (Berlin definition). Venous thromboembolism (deep vein thrombosis or pulmonary embolism) or arterial (acute myocardial infarction or stroke).
Measure: Proportion of patients that worsen Time: Day 10 +/- 1Description: Mortality from any cause
Measure: Mortality from any cause at day 28 Time: Day 28Description: Proportion of subjects that requires admission to the ICU
Measure: Proportion of subjects that requires admission to the ICU Time: From study start to day 28Description: Proportion of subjects requiring non-invasive mechanical ventilation
Measure: Proportion of subjects requiring non-invasive mechanical ventilation Time: From study start to day 28Description: Proportion of subjects requiring invasive mechanical ventilation.
Measure: Proportion of subjects requiring invasive mechanical ventilation. Time: From study start to day 28Description: Proportion of subjects with some organ failure
Measure: Proportion of subjects with some organ failure Time: From study start to day 28Description: Proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline
Measure: Proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline Time: From study start to day 28Description: Proportion of subjects with pathological angioTAC at day 10 +/-1
Measure: Proportion of subjects with pathological angioTAC Time: At day 10 +/-1Description: Proportion of subjects with improvement in chest radiography
Measure: Proportion of subjects with improvement in chest radiography Time: At day 10 +/-1Description: Proportion and median hospital discharge between patients in both groups.
Measure: Proportion and median hospital discharge between patients in both groups. Time: From study start to day 28Description: Titration score
Measure: Titration score Time: From study start to day 28Description: Ferritin score
Measure: Ferritin score Time: From study start to day 28Description: D-dimer modification score
Measure: D-dimer modification score Time: From study start to day 28Description: Adverse events (total and serious)
Measure: Adverse events (total and serious). Time: From study start to day 28Description: Related adverse events (total and serious).
Measure: Related adverse events (total and serious). Time: From study start to day 28Description: Clinically relevant major and non major hemorrhages.
Measure: Clinically relevant major and non major hemorrhages. Time: From study start to day 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports